ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
PCN151 COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR WOMEN WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER IN FRANCE
Value in Health
◽
10.1016/j.jval.2019.09.347
◽
2019
◽
Vol 22
◽
pp. S464-S465
Author(s):
A. Gherardi
◽
C. Ouared
◽
B. Tehard
◽
S. Roze
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Cost Effectiveness Analysis
◽
Effectiveness Analysis
Download Full-text
Related Documents
Cited By
References
Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system
Journal of Medical Economics
◽
10.1080/13696998.2020.1821039
◽
2020
◽
Vol 23
(11)
◽
pp. 1340-1344
Author(s):
Rodrigo Shimabukuro Ho
◽
Mariana Mioti Sebastião
◽
João Paulo Venezian de Carvalho
◽
Tomás Neves
◽
Micha Nussbaum
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Healthcare System
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Cost Effectiveness Analysis
◽
Private Healthcare
◽
Effectiveness Analysis
Download Full-text
Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
BMC Health Services Research
◽
10.1186/s12913-020-05445-6
◽
2020
◽
Vol 20
(1)
◽
Author(s):
Lee Cheng Phua
◽
Soo Chin Lee
◽
Kwong Ng
◽
Mohamed Ismail Abdul Aziz
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Cost Effectiveness Analysis
◽
Effectiveness Analysis
Download Full-text
Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan
Clinical Drug Investigation
◽
10.1007/s40261-021-01017-6
◽
2021
◽
Author(s):
Yugo Chisaki
◽
Yoshiki Kuwada
◽
Chikako Matsumura
◽
Yoshitaka Yano
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Cost Effectiveness Analysis
◽
Effectiveness Analysis
Download Full-text
PCN122 COST-EFFECTIVENESS ANALYSIS OF TRASUTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR WOMEN WITH HER2+ ADJUVANT BREAST CANCER IN FRANCE
Value in Health
◽
10.1016/j.jval.2019.09.318
◽
2019
◽
Vol 22
◽
pp. S459
◽
Cited By ~ 1
Author(s):
A. Gherardi
◽
R. Sellami
◽
B. Tehard
◽
S. Roze
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Cost Effectiveness Analysis
◽
Effectiveness Analysis
◽
Adjuvant Breast Cancer
Download Full-text
Cost-Effectiveness Analysis: Lymph Node Transfer vs Lymphovenous Bypass for Breast Cancer-Related Lymphedema
Journal of the American College of Surgeons
◽
10.1016/j.jamcollsurg.2021.02.013
◽
2021
◽
Author(s):
Yurie Sekigami
◽
Sydney Char
◽
Cate Mullen
◽
Kathryn Huber
◽
Yu Cao
◽
...
Keyword(s):
Breast Cancer
◽
Lymph Node
◽
Cost Effectiveness
◽
Cost Effectiveness Analysis
◽
Effectiveness Analysis
◽
Breast Cancer Related Lymphedema
◽
Lymph Node Transfer
Download Full-text
58P Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
Annals of Oncology
◽
10.1016/j.annonc.2021.03.072
◽
2021
◽
Vol 32
◽
pp. S45
Author(s):
X. Guan
◽
H-C. Li
◽
Q-J. Chen
◽
B. Hua
◽
J-J. Li
◽
...
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Early Breast Cancer
◽
Cost Effectiveness Analysis
◽
Chinese Patients
◽
Trastuzumab Emtansine
◽
Her2 Positive
◽
Effectiveness Analysis
Download Full-text
Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil
Expert Review of Pharmacoeconomics & Outcomes Research
◽
10.1080/14737167.2021.1909478
◽
2021
◽
pp. 1-10
Author(s):
Carlos Henrique Botelho
◽
Maria Del Pilar Estevez-Diz
◽
Alessandro Gonçalves Campolina
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Early Breast Cancer
◽
Cost Effectiveness Analysis
◽
Effectiveness Analysis
Download Full-text
PCN69 Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer: [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination
Value in Health
◽
10.1016/j.jval.2020.08.206
◽
2020
◽
Vol 23
◽
pp. S433-S434
Author(s):
G. Vondeling
◽
E. Palaka
◽
C. Livings
◽
J. Naik
◽
W. Sullivan
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Cost Effectiveness
◽
Metastatic Breast
◽
Cost Effectiveness Analysis
◽
Novel Therapies
◽
Effectiveness Analysis
Download Full-text
Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
Breast Cancer Research and Treatment
◽
10.1007/s10549-014-3107-3
◽
2014
◽
Vol 147
(2)
◽
pp. 443-443
◽
Cited By ~ 1
Author(s):
Vakaramoko Diaby
◽
Georges Adunlin
◽
Simon B. Zeichner
◽
Kiran Avancha
◽
Gilberto Lopes
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Cost Effectiveness
◽
Hormone Receptor
◽
Metastatic Breast
◽
Cost Effectiveness Analysis
◽
Hormone Receptor Positive
◽
Effectiveness Analysis
Download Full-text
A Cost-Effectiveness Analysis of Palbociclib and other Aromatase Inhibitors for Treatment of Advanced Breast Cancer
Value in Health
◽
10.1016/j.jval.2016.03.1589
◽
2016
◽
Vol 19
(3)
◽
pp. A150
◽
Cited By ~ 6
Author(s):
K Bhattacharya
◽
Y Yang
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Advanced Breast Cancer
◽
Aromatase Inhibitors
◽
Cost Effectiveness Analysis
◽
Advanced Breast
◽
Effectiveness Analysis
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close